Glucagonoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

The incidence of glucagonoma is approximately 0.0005 per 100,000 individuals worldwide. Glucagonoma affects men and women equally. The median age of diagnosis is the fifth decade.

Epidemiology and Demographics

Incidence

Annual incidence is 0.01 to 0.1 new cases per 100,000.^[1]
Most glucagonomas are sporadic but up to 20 percent may be associated with the multiple endocrine neoplasia syndrome type 1. Glucagonomas occur in only 3 percent of MEN1 patients.^[2]^[3]

Age

Patients typically present in their fifth decade with lesions mainly located in the tail of the pancreas,
When associated with MEN 1, patients present at a younger age of around 33 years.^[4]^[5]

Gender

Glucagonoma affects men and women equally.

References

↑ Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P; et al. (2012). “ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes”. Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
↑ Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D; et al. (2004). “Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry”. Gastroenterol Clin Biol. 28 (11): 1075–81. PMID 15657529.
↑ Rajesh V. Thakker, Paul J. Newey, Gerard V. Walls, John Bilezikian, Henning Dralle, Peter R. Ebeling, Shlomo Melmed, Akihiro Sakurai, Francesco Tonelli & Maria Luisa Brandi (2012). “Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)”. The Journal of clinical endocrinology and metabolism. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327. Unknown parameter |month= ignored (help)
↑ Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). “The glucagonoma syndrome. Clinical and pathologic features in 21 patients”. Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
↑ Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). “The glucagonoma syndrome. Clinical and pathologic features in 21 patients”. Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.

Template:WH Template:WS

[pmid22261919-1] Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P; et al. (2012). “ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes”. Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.

[pmid15657529-2] Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D; et al. (2004). “Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry”. Gastroenterol Clin Biol. 28 (11): 1075–81. PMID 15657529.

[3] Rajesh V. Thakker, Paul J. Newey, Gerard V. Walls, John Bilezikian, Henning Dralle, Peter R. Ebeling, Shlomo Melmed, Akihiro Sakurai, Francesco Tonelli & Maria Luisa Brandi (2012). “Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)”. The Journal of clinical endocrinology and metabolism. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327. Unknown parameter |month= ignored (help)

[pmid86066272-4] Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). “The glucagonoma syndrome. Clinical and pathologic features in 21 patients”. Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.

[pmid8606627-5] Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). “The glucagonoma syndrome. Clinical and pathologic features in 21 patients”. Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.

[1]

[2]

[3]

[4]

[5]